Impact of a Pharmacist-Led Warfarin to Direct Oral Anticoagulant Conversion Initiative during the COVID-19 Pandemic.

Innovations in Pharmacy Pub Date : 2022-04-02 eCollection Date: 2022-01-01 DOI:10.24926/iip.v13i1.4491

Kelsey Mews, Audrey Umbreit, Emily Holm, Kelsie Davis, Ellen Kelly, Carson Reinhardt, Allison Young, Joseph Flynn

{"title":"Impact of a Pharmacist-Led Warfarin to Direct Oral Anticoagulant Conversion Initiative during the COVID-19 Pandemic.","authors":"Kelsey Mews, Audrey Umbreit, Emily Holm, Kelsie Davis, Ellen Kelly, Carson Reinhardt, Allison Young, Joseph Flynn","doi":"10.24926/iip.v13i1.4491","DOIUrl":null,"url":null,"abstract":"Purpose: To assess the impact of a pharmacist-led warfarin to DOAC conversion initiative during the COVID-19 pandemic. Methods: Patients who were prescribed warfarin and followed with the anticoagulation clinic for INR monitoring were assessed by outpatient clinical pharmacists as potential candidates for transition to DOACs from March-August 2020. Results: 530 patients were assessed for transition to DOACs, of which 373 (70.4%) were deemed by clinical pharmacists to be candidates for DOACs. Of the patients who were candidates for DOACs, 66 (17.7%) were transitioned from warfarin to a DOAC. Of the patients who transitioned to a DOAC, 59 (89.4%) remained on a DOAC after one year. Conclusion: Outpatient clinical pharmacists are an effective resource to help identify patients who are candidates for DOACs and assist with transition from warfarin. Further, high persistence rates with DOAC therapy after one year demonstrate the positive impact of the clinical pharmacist on medication adherence.","PeriodicalId":13646,"journal":{"name":"Innovations in Pharmacy","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7a/c9/21550417-13-01-4491.PMC9598966.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Innovations in Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24926/iip.v13i1.4491","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To assess the impact of a pharmacist-led warfarin to DOAC conversion initiative during the COVID-19 pandemic. Methods: Patients who were prescribed warfarin and followed with the anticoagulation clinic for INR monitoring were assessed by outpatient clinical pharmacists as potential candidates for transition to DOACs from March-August 2020. Results: 530 patients were assessed for transition to DOACs, of which 373 (70.4%) were deemed by clinical pharmacists to be candidates for DOACs. Of the patients who were candidates for DOACs, 66 (17.7%) were transitioned from warfarin to a DOAC. Of the patients who transitioned to a DOAC, 59 (89.4%) remained on a DOAC after one year. Conclusion: Outpatient clinical pharmacists are an effective resource to help identify patients who are candidates for DOACs and assist with transition from warfarin. Further, high persistence rates with DOAC therapy after one year demonstrate the positive impact of the clinical pharmacist on medication adherence.

Abstract Image

查看原文本刊更多论文

药剂师主导的华法林对COVID-19大流行期间直接口服抗凝药物转换倡议的影响

目的:评估在COVID-19大流行期间药剂师主导的华法林对DOAC转换倡议的影响。方法:2020年3月至8月，门诊临床药师对处方华法林并在抗凝诊所进行INR监测的患者进行评估，作为过渡到doac的潜在候选人。结果:530例患者被评估为过渡到DOACs，其中373例(70.4%)被临床药师认为是DOACs的候选人。在DOAC候选患者中，66例(17.7%)从华法林过渡到DOAC。在过渡到DOAC的患者中，59例(89.4%)在一年后继续使用DOAC。结论:门诊临床药师是一种有效的资源，可以帮助确定doac候选患者，并协助从华法林过渡。此外，一年后DOAC治疗的高持续率表明临床药师对药物依从性的积极影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Innovations in Pharmacy

自引率

0.00%

发文量